melanoma has not been shown to improve survival to date, an inverse relationship between disease burden and response to immunotherapy is generally acknowledged. Thus, a reasonable presumptive rationale exists for early detection of asymptomatic metastasis. Every oncologist ostensibly prefers to treat a patient with isolated lung metastases rather than lung and brain metastasis.
The work of Lee and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC), patterns and timing of initial relapse in pathologic stage II melanoma patients, continues the effort started by Romano et al. 2 in 2010, who assessed patterns of follow-up assessment for stage 3 disease and used those findings to make recommendations regarding follow-up evaluation. The current article addresses the very salient question regarding recurrence in the heterogeneous stage 2 disease population. The authors' findings continue to validate the American Joint Committee on Cancer (AJCC) stage subgroupings, namely, that disease stages 2A, B, and C behave very differently in terms of rates and patterns of recurrence. However, they nicely contextualize those differences in a way that potentially directs a follow-up strategy.
The authors define a rational follow-up strategy by delineating the time course and location of recurrences according to substage and by pairing those recurrences with the methods of detection. Interestingly, the most common method for detecting recurrence is detection by the patients themselves. Of course, this was a somewhat self-fulfilling prophesy in this retrospective analysis because no standard imaging protocols were followed, and imaging was generally considered to be optional by NCCN guidelines. It remains unknown how many patients might have had asymptomatic recurrence detected by imaging had it been used routinely. Nevertheless, the authors' study points out one of the constant, repeatedly validated truths in medicine: a thorough history and physical examination directed at detecting signs and symptoms of recurrent disease remain the mainstay of follow-up assessment. Imaging, frankly, is not a substitute for physical examination, and the embarrassing truth of the matter is that many cancer specialists never ask melanoma patients to disrobe for a proper physical examination.
Sherry and his colleagues at the National Cancer Institute (NCI) analyzed data across multiple clinical trials of immunotherapy for high-risk stages 2, 3, and 4 melanoma patients. The difference between this study and the investigation from MSKCC was that routine surveillance computed tomography (CT) imaging was prescribed in the NCI clinical trials. Sherry and colleagues found that for stage 2 patients, the first site of recurrence was locoregional half the time and systemic the other half. One third of stage 3 patients had locoregional recurrence, and two thirds had systemic recurrence. The use of CT scans detected 59% of recurrences overall and 75% of the patients with asymptomatic systemic recurrences. Laboratory studies were essentially useless.
Both of these studies begin to explore the more provocative underlying question: how should we tailor the follow-up plan, including the use of surveillance imaging studies, to match the risk of recurrence? Although the AJCC staging system is the obvious starting point for discerning differences in prognosis, we submit that anatomic staging uses technology that is hundreds to thousands of years old, namely, what a physician can see or feel and what a pathologist can visualize under the microscope. Nonetheless, clinicopathologic factors such as Breslow thickness, ulceration, and sentinel lymph node status provide invaluable prognostic information.
However, TNM staging carries significant limitations. For example, every patient with a small focus of metastasis in a sentinel lymph node is considered stage 3, yet the 5-year survival rate ranges from 15 to 85 % depending on other factors. Prognostic models that incorporate other factors such as age, anatomic location of the primary tumor, and non-sentinel node metastasis can provide better estimates of prognosis than the AJCC stage alone.
Whether a physician chooses to use the AJCC's online model, 3 available at www.melanomaprognosis.net, the model developed at the University of Louisville at www. melanomacalculator.com (also available as a free iPhone or Android app), 4 or another model, building a rational follow-up plan begins with an individualized assessment of recurrence risk. The future of optimizing this risk assessment clearly lies in genetic and molecular profiling. A validated polymerase chain reaction (PCR)-based multigene assay for cutaneous melanoma is available, 5, 6 although how such a test should influence a follow-up plan-alone or in conjunction with clinicopathologic factor models-remains unclear and warrants further investigation.
Although it remains to be seen whether earlier detection of melanoma recurrence will improve survival in the era of effective immunotherapy for melanoma, development of a rational, standardized follow-up system tailored to individual patient risk seems to be an appropriate step in the right direction. Critics will point to the cost of imaging and demand cost-effectiveness studies. However, we argue that melanoma represents virtually the only cancer in which patients can have a 50% or greater risk of recurrence, and the NCCN guidelines allow for optional imaging.
How will we pay for it? We suggest that we start by eliminating all 3-6 month laboratory and imaging tests to detect asymptomatic recurrence of patients with cancers for which no effective salvage therapies exist. Physicians reflexively and routinely order such studies for follow-up of patients with pancreatic cancer, extrahepatic cholangiocarcinoma, and gastric and esophageal adenocarcinoma, although we know that systemic therapy for recurrent disease offers little benefit. In fact, it can be argued that the benefit for these patients is defined by Q-TWiST (Quality Time WIthout Symptoms or Toxicity-knowledge of recurrence). We certainly rob many such patients of the time without knowledge of recurrence to begin systemic therapy for asymptomatic metastasis, which often promises limited or no real benefit in terms of quantity or quality of life. However, in the case of advanced melanoma, we currently have effective therapies that can improve survival and offer the hope of cure. For potential maximization of that promise, should we not strongly consider personalized follow-up plans to match the risk of recurrence? The new era of melanoma treatment demands new surveillance strategies.
